Request a Quote

Neutrophil Activation in Nontuberculous Lung Disease

Neutrophil activation begins early when the lung encounters a nontuberculous mycobacterium, but the same response can harm the airway it is meant to defend. A cross sectional study compared three adult groups: patients with nontuberculous mycobacterial pulmonary disease, people with antibody deficiency who seldom acquire the infection despite bronchiectasis, and healthy controls. Both patient groups arrived with primed neutrophils, yet their opsonophagocytic behavior differed. The findings matter to anyone weighing host directed therapy or the place of rifabutin based regimens in nontuberculous disease.

Why neutrophil activation is worth measuring

These mycobacteria live in the environment and cause chronic lung disease, usually in people with structural damage or weak immunity. Bronchiectasis is the most common background. Neutrophils gather in those airways, and their products drive the tissue injury that pushes the disease along. The result is a bind. The cells are there to control infection, but their persistence makes the lung worse.

The study chose an unusual contrast to examine that bind. People with common variable immunodeficiency or X linked agammaglobulinemia lack antibody production and often have bronchiectasis, yet they rarely develop nontuberculous infection. If neutrophils or serum factors accounted for that resistance, the comparison should show it.

The framing separates two questions that tend to blur. One is whether the cells are activated. The other is whether they can ingest and kill the organism once it has been tagged. A group can score high on one and low on the other.

How the three groups were compared

The design was cross sectional, using whole blood assays and serum based opsonophagocytosis. This table sets each question against the method and the group sizes.

Question

Method

Groups and sizes

Baseline neutrophil phenotype

Flow cytometry for CD15, CD64, CD66b

NTM disease 15, antibody deficiency 18, healthy 16

Phagocytosis of mycobacteria

FITC labeled Mycobacterium abscessus and Mycobacterium avium

Pooled experiments, n reported per assay

Opsonization capacity

Healthy donor neutrophils plus heat inactivated patient serum

NTM 9, antibody deficiency 9, healthy 8

Neutrophil derived products

Serum and sputum protein measurement

NTM 15, antibody deficiency 15, healthy 15 in serum

Statistical comparison

Unpaired tests or Kruskal Wallis with post hoc correction

Significance set at p below 0.05, two tailed

Sample sizes were modest and varied by assay, which the report states. Bronchiectasis was present in 14 of 15 patients with nontuberculous disease, or 93 percent, and in 13 of 18 with antibody deficiency, or 72 percent. Controls had no chronic lung disease.

Baseline activation findings

Both patient groups differed from healthy donors at rest. In the nontuberculous group, CD66b mean fluorescence intensity was 7604 with standard deviation 4122, against 2831 with standard deviation 2391 in controls, at p equal to 0.002. In the antibody deficiency group, CD15 was lower at 28675 with standard deviation 11875 versus 48755 with standard deviation 26559, at p equal to 0.01.

People with antibody deficiency also had higher CD16 and CD64, both Fc gamma receptors, and all received immunoglobulin replacement. That detail changes the opsonization setting regardless of any cell intrinsic effect. Within either patient group, CD15, CD64, and CD66b did not shift with treatment status, all p values above 0.05.

Marker or function

NTM disease group

Antibody deficiency group

Healthy comparators

Reported p value

Baseline CD66b MFI

7604, SD 4122

Not the main site of difference

2831, SD 2391

0.002, disease versus healthy

Baseline CD15 MFI

Reduced in some comparisons

28675, SD 11875

48755, SD 26559

0.01, deficiency versus healthy

Phagocytosis with M. avium serum

40 percent, SD 12 versus 21 percent, SD 16

54 percent, SD 25 versus 24 percent, SD 27

52 percent, SD 25 versus 26 percent, SD 22

0.02, 0.001, 0.005

Bronchiectasis prevalence

14 of 15, 93 percent

13 of 18, 72 percent

0

Not the primary endpoint

Immunoglobulin replacement

0

18 of 18, 100 percent

0

Descriptive

The counterintuitive phagocytosis result

The serum opsonization assay produced the sharpest turn. When healthy donor neutrophils received Mycobacterium avium incubated with patient serum, ingestion rose compared with healthy serum. In the healthy series the values were 52 percent with standard deviation 25 against 26 percent with standard deviation 22, at p equal to 0.005. The same direction held in the nontuberculous group, 40 percent versus 21 percent at p equal to 0.02, and in the antibody deficiency group, 54 percent versus 24 percent at p equal to 0.001.

The wording carries the caution. Serum increased uptake in the assay. It does not follow that these patients clear the organism better, since the nontuberculous group was already infected. Higher opsonophagocytosis may reflect prior exposure and antibody formation rather than protection. The report treats it as a description of serum capacity, not a resistance mechanism.

That qualifier is easy to lose in a brief summary. A percentage with a p value looks decisive. Here the authors explicitly leave open whether the neutrophil differences came before the disease or followed from it.

What the antibody deficiency group adds

This cohort was chosen because its members have bronchiectasis without usually developing nontuberculous infection. Their neutrophils also looked primed, with lower CD15 and higher CD16 and CD64. Their clinical history nevertheless differs from the disease group.

The contrast weakens any simple claim that bronchiectasis alone produces the phenotype. If it did, the two groups would match on every measure. They do not. Opsonization, immunoglobulin replacement, or organism exposure separates them, and the data do not settle which factor matters most.

For treatment thinking this is where host directed ideas become both promising and speculative. A primed state can be measured. Turning it into a target requires knowing whether it helps or hurts at a given stage, and the study does not claim that knowledge.

Where rifabutin and macrolide regimens sit

Regimens for nontuberculous pulmonary disease usually pair a macrolide with a rifamycin, adding ethambutol for some organisms. Rifabutin is the rifamycin most used for Mycobacterium avium complex disease, while rifampicin appears in other settings. Patients here were taking azithromycin, clarithromycin, and other antibiotic prophylaxis as recorded by group.

The connection to neutrophil biology is indirect but real. Effective therapy lowers organism burden, which may reduce the ongoing stimulus that keeps neutrophils primed. Nothing in this cross sectional dataset proves that sequence. The point is that any attempt to use host response as a treatment marker must account for the antimicrobial regimen already in place.

Rifabutin and rifampicin also have important interactions through host enzymes and transporters. Rifampicin strongly induces CYP3A4 and P glycoprotein. Those properties shape exposure and combination design in ways a neutrophil assay cannot see. Microbial clearance and host inflammation belong together, not substituted for each other.

Practical implications

A few working principles follow.

  • Read activation markers and functional assays apart. A primed cell is not automatically a better phagocyte.
  • Treat serum effects as exposure history until shown otherwise. Prior infection can raise opsonizing capacity.
  • Record bronchiectasis and immunoglobulin replacement when comparing groups, since both shift the baseline.
  • Avoid cause claims from a cross sectional snapshot. Timing is unresolved here.
  • Keep the antimicrobial regimen in view when reading host markers, including macrolide and rifabutin based regimens.
  • Prefer functional endpoints over surface markers alone when designing host directed work.

Limitations

The sample was small, 15 to 18 in the main groups and fewer in some assays, and the design was cross sectional. The antibody deficiency group all received immunoglobulin replacement, a confounder for serum experiments. Several neutrophil derived proteins, including elastase in some comparisons, did not differ significantly. The authors state that whether the changes preceded or resulted from infection remains open. The work is descriptive host biology, not a trial of an intervention.

Bottom line

Neutrophil activation appeared in both disease and antibody deficiency, with higher CD66b in the disease group and lower CD15 in the deficiency group. Serum from patients increased mycobacterial uptake in vitro, a result that may reflect prior exposure rather than protection. This is a careful cross sectional comparison, not a causal account. For rifabutin and macrolide based care, the lesson is to read host markers alongside the regimen and to resist turning a single surface marker into a decision.

FAQ

What is nontuberculous mycobacterial pulmonary disease?

It is a chronic lung infection caused by mycobacteria other than the organisms that cause tuberculosis. Mycobacterium avium complex and Mycobacterium abscessus are among the commonest causes. The disease usually develops in people with structural lung problems such as bronchiectasis, or with immune suppression. Treatment is long, often combines several antibiotics, and aims to reduce organism burden and protect lung function. The study described here looked at the host response in people who already had the disease, compared with two other groups.

What does neutrophil activation mean in this context?

It means the cells show surface and functional signs of being in a prepared or inflamed state. In this study the disease group had higher CD66b expression and the antibody deficiency group had lower CD15 expression than healthy donors. Both patterns are consistent with priming, a state in which cells are ready to degranulate or respond strongly. Activation by itself does not tell you whether the cells are controlling the organism or contributing to tissue damage.

Why study people with antibody deficiency?

Because they are a natural comparison. They often have bronchiectasis, which is the usual background for nontuberculous lung disease, yet they seldom acquire the infection. If neutrophils or serum factors explained that difference, comparing them with patients who did develop disease would reveal it. The study found that both groups had primed neutrophils, so bronchiectasis alone does not explain the phenotype. The reason for their lower infection rate remains unresolved in this dataset.

Did patient serum make neutrophils engulf more bacteria?

Yes, in the laboratory assay. Serum from each patient group increased uptake of labeled mycobacteria by healthy donor neutrophils compared with healthy serum. In one series the values were 52 percent versus 26 percent. The authors interpret this as a measure of opsonization capacity rather than proof of better protection. People with established disease have had time to develop responses to the organism, so higher uptake may be a trace of past exposure.

How does rifabutin fit into this picture?

Rifabutin is a rifamycin antibiotic commonly used in regimens for Mycobacterium avium complex disease, alongside a macrolide and often ethambutol. Rifampicin appears in other nontuberculous settings. This study did not test either drug. The connection is that effective treatment changes organism burden, which may change the stimulus that keeps neutrophils primed. Rifabutin and rifampicin also have important host enzyme and transporter interactions, so their pharmacology belongs in any full account of these patients.

Can a neutrophil marker guide treatment decisions?

Not on this evidence. The markers described differ between groups, but the study was cross sectional and small. It cannot show that a marker came before the disease or that changing the marker would change outcomes. At present such measurements are better viewed as research tools. A marker would need prospective validation, ideally showing that it predicts progression or treatment response before it informs a clinical choice.

What were the main statistical findings?

Baseline CD66b in the disease group was 7604 versus 2831 in healthy donors, with p equal to 0.002. CD15 in the antibody deficiency group was 28675 versus 48755, with p equal to 0.01. Opsonophagocytosis comparisons gave p values of 0.005, 0.02, and 0.001 across the three series. Significance was set at p below 0.05 with correction for multiple comparisons. Several other measurements, including neutrophil derived proteins, did not reach significance.

What does cross sectional mean and why does it matter here?

It means the researchers measured everyone at one point in time rather than following them forward. The design is efficient for comparing groups but weak for timing. If a marker differs between patients and controls, the study cannot say whether the marker helped cause the disease or appeared as a result. That limitation is central here, because the authors explicitly leave open whether neutrophil activation precedes or follows established infection.

Were the treatment regimens relevant to the results?

Potentially. Patients with nontuberculous disease were on antibiotics such as azithromycin or clarithromycin, and those with antibody deficiency received immunoglobulin replacement. Both can shape the measurements. The report records these exposures by group rather than adjusting for each drug, so a reader should treat the group comparisons as descriptive. Any future host marker study would need to account for the regimen in more detail.

What should a respiratory researcher take from this?

The useful lesson is to pair phenotype with function. A surface marker told the team that cells were primed, while the opsonophagocytosis assay told them something different about serum capacity. Those two results point in different directions, and collapsing them into one score would lose the finding. For anyone designing host directed work around nontuberculous disease, that separation is a practical starting point.

My Instagram